Dr. Marty Makary has left his post as commissioner of the U.S. Food and Drug Administration, the White House said Tuesday.
The White House said President Donald Trump approved Makary’s departure and designated Kyle Diamantas, the agency’s deputy commissioner for human food, to serve as acting commissioner.
Makary’s stint at the FDA lasted about 13 months; news reports described his time in office as frequently contentious, with recurring clashes inside the agency and public disputes.
Several outlets reported that the resignation followed weeks of mounting pressure from senior administration officials at the White House and the Department of Health and Human Services, as well as from outside stakeholders.
Media coverage linked the exit in part to internal disagreements over recent decisions on flavored e-cigarette products, reporting that Makary opposed approving certain fruit-flavored vaping items and had clashed with other officials on the matter.
Accounts of Makary’s communications around his departure said he cited agency actions and priorities, including efforts to accelerate specific drug review processes and backing for research into areas such as psychedelic medicines and hormone therapies for menopause.
Administration spokespeople have not named a permanent successor and said the process to select a long‑term commissioner is ongoing.
Makary had been scheduled to appear before the Senate Appropriations Committee to discuss the FDA’s fiscal 2027 budget the day after his resignation became public, according to reports.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!